You are here: Industry Insights > cancer

News List

Bavarian Nordic hit by cancer immunotherapy failure pharmatimes
September 19, 2017
Bavarian Nordic saw its shares plummet as much as 50 percent in the wake of news that the firm’s cancer immunotherapy ProstVac failed to prolong survival in men with a particular type of prostate cancer.
Novel combination therapy for cancer identified europeanpharmaceuticalreview
September 19, 2017
Artemisinin, a potent anti-malarial drug, has been widely hailed as a promising alternative cancer treatment…
Chemotherapy pain may be eased by jet-lag drug europeanpharmaceuticalreview
September 19, 2017
Painful side effects from cancer medicines could be tackled with a drug that eases the effects of jetlag…
Eisai announces combined clinical trial results on cancer biospectrumasia
September 14, 2017
Appropriate monitoring of Quality-Of-Light and continuous treatment via anticancer agents allow for maximum patient benefit.
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Sta worldpharmanews
September 07, 2017
The first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride
This is how belly fat could increase your cancer risk worldpharmanews
August 28, 2017
It's been well established that obesity is a contributor to cancer risk, but how it actually causes cancer is still a question that hasn't been fully explained
NICE turns down kidney cancer drugs pharmatimes
August 15, 2017
It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
Bayer secures one-two treatment for liver cancer after EU approval pharmafile
August 08, 2017
Bayer has announced that it has received European Commission approval for its treatment of hepatocellular carcinoma, a type of liver cancer, as second-line treatment.
NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment pharmafile
August 07, 2017
Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination with gemcitabine...
Bristol-Myers Squibb’s $2.3 billion gamble to boost cancer pipeline pharmafile
August 07, 2017
Bristol-Myers Squibb has agreed a deal to acquire IFM Therapeutics for a potential $2.3 billion. The latter is a biotech that only last year completed its series A funding, gaining $27 million to back its venture in the process.

Previous page 1 2 3 4 Next page